Trial Profile
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatin receptor ligands (SRL) treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Acronyms CHIASMA OPTIMAL; OPTIMAL
- Sponsors Chiasma
- 17 Apr 2023 This trial been completed in Slovenia, according to European Clinical Trials Database record.
- 20 Mar 2023 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 13 Jun 2022 Open-label extension part results published in the Amryt Pharma Media Release